Group 1 - GIC Private Limited increased its stake in Basilea Pharmaceutica AG-B (02616) by 904,500 shares at a price of HKD 5.8476 per share, totaling approximately HKD 5.2892 million [1] - After the increase, GIC's total shareholding rose to about 119 million shares, representing an ownership percentage of 8.06% [1] - GIC's consistent buying activity since first disclosing a 5.49% stake on August 18 indicates strong confidence in Basilea's core value and long-term growth potential [1] Group 2 - GIC has made multiple purchases, with increases reported on October 13 and November 10, raising its stake to 7.11% before the latest increase [1] - Over the four-month period from August 18 to December 23, GIC has accumulated more than 38 million additional shares, reflecting a steady growth in ownership [1]

Group 1 - GIC Private Limited increased its stake in Basestone Pharmaceuticals-B (02616.HK) by purchasing 904,500 shares at an average price of HKD 5.8476 per share, totaling approximately HKD 5.2892 million [1] - Following this transaction, GIC's total shareholding in Basestone Pharmaceuticals-B rose to 118,892,000 shares, increasing its ownership percentage from 7.99% to 8.06% [1]

Core Viewpoint - The report highlights the top short-selling stocks in the Hong Kong market, indicating significant investor sentiment and potential market movements for these companies [1][2]. Group 1: Top Short-Selling Ratios - Sun Hung Kai Properties (80016), BYD Company (81211), and JD Health (86618) have the highest short-selling ratios at 100.00% [1][2]. - SenseTime (80020) follows with a short-selling ratio of 87.67%, while Xiaomi Group (81810) has a ratio of 84.37% [2]. Group 2: Top Short-Selling Amounts - Xiaomi Group leads in short-selling amount with HKD 1.43 billion, followed by Alibaba (09988) at HKD 1.368 billion and Tencent Holdings (00700) at HKD 1.251 billion [1][2]. - China Ping An (02318) and Meituan (03690) also feature prominently with short-selling amounts of HKD 1.115 billion and HKD 956 million, respectively [2]. Group 3: Top Short-Selling Deviation Values - Xiaomi Group (81810) has the highest deviation value at 41.14%, indicating a significant difference from its average short-selling ratio [1][2]. - BYD Company (81211) follows closely with a deviation value of 40.41%, while Far East Consortium (00035) has a deviation of 33.08% [2].

Core Viewpoint - The stock of Basilea Pharmaceutica (02616) has risen over 5%, currently at 6.07 HKD, following the announcement that its RET inhibitor, Pralsetinib (100 mg), has been included in the latest National Medical Insurance Drug List in China, effective January 1, 2026 [1] Company Developments - Basilea has successfully advanced four innovative drugs to market approval, with three of these products having completed clinical trials and registration in China, now included in the national medical insurance list [1] - The inclusion of Pralsetinib in the insurance list is expected to accelerate its market penetration, as noted in a report by Tianfeng Securities published in August [1] Pipeline and Technology - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] - Basilea's innovative internal ADC technology platform features proprietary linkers designed to enhance the selective release of effective payloads in tumors, supporting multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for the company's future growth [1]

Group 1 - Company shares of 基石药业-B (02616) increased by over 5%, reaching a price of 6.07 HKD with a trading volume of 22.7042 million HKD [1] - The company announced that its RET inhibitor, 普吉华 (普拉替尼胶囊, 100mg), has been successfully included in the latest National Medical Insurance Catalog, effective from January 1, 2026 [1] - To date, 基石药业 has successfully advanced four innovative drugs to market approval, with three of them having completed clinical trials and registration in China, now included in the national insurance catalog [1] Group 2 - Tianfeng Securities published a report in August, predicting that the inclusion of 普拉替尼 in the insurance catalog is expected to accelerate its market penetration [1] - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] - The innovative internal ADC technology platform of the company features optimized proprietary linkers to improve the selective release of effective payloads in tumors, supporting multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for future development [1]

Core Viewpoint - 基石药业's RET inhibitor, Pralsetinib (普吉华®), has been included in the latest National Medical Insurance Drug List in China, effective January 1, 2026, which is expected to enhance its market penetration and sales growth [1] Group 1: Company Developments - 基石药业's stock rose by 5.57% to HKD 6.07, with a trading volume of HKD 22.7042 million [1] - The company has successfully advanced four innovative drugs to market approval, with three of them having completed clinical trials and registration in China, now included in the national medical insurance list [1] Group 2: Market Expectations - Tianfeng Securities reported in August that the inclusion of Pralsetinib in the insurance list is anticipated to accelerate its market uptake [1] - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] Group 3: Technological Advancements - 基石药业 has developed an innovative internal ADC technology platform, characterized by optimized proprietary linkers to improve tumor-selective payload release [1] - The platform supports multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for the company's future growth [1]

Group 1 - The stocks of Zhaoyan New Drug (06127.HK) increased by 5.54% [1] - Rongchang Biologics (09995.HK) saw a rise of 3.95% [1] - WuXi AppTec (02268.HK) experienced a growth of 3.05% [1] - Cornerstone Biosciences-B (02616.HK) rose by 2.86% [1]

Group 1 - Core viewpoint: 基石药业-B (02616) shares rose over 4%, currently trading at 5.82 HKD with a transaction volume of 24.98 million HKD, following the announcement of its drug being included in the national medical insurance list [1] - The drug, 普吉华 (普拉替尼胶囊, 100 mg), will be officially included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by the National Healthcare Security Administration of China, effective from January 1, 2026 [1] - On December 4, non-executive director 胡正国 increased his stake in 基石药业 by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, raising his total holdings to 3.471 million shares, which represents 0.24% of the company [1]

Core Viewpoint - The stock of Basestone Pharmaceuticals (02616) has seen an increase of over 4%, currently trading at 5.82 HKD, with a transaction volume of 24.98 million HKD, following the announcement of its drug being included in the national medical insurance list in China [1] Group 1 - Basestone Pharmaceuticals announced that its drug, Pulatinib (100 mg capsules), has been included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List published by the National Healthcare Security Administration of China, which will take effect on January 1, 2026 [1] - Following this announcement, the stock price of Basestone Pharmaceuticals rose by 3.93% [1] Group 2 - On December 4, the non-executive director Hu Zhengguo increased his holdings in Basestone Pharmaceuticals by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD [1] - After this purchase, Hu Zhengguo's total shareholding in the company increased to 3.471 million shares, representing a holding percentage of 0.24% [1]

Group 1 - The core point of the article is that 基石药业's drug, 普吉华 (普拉替尼胶囊, 100mg), has been included in the latest National Medical Insurance Drug List in China, which will take effect on January 1, 2026 [1] - Following the announcement, 基石药业's stock price increased by over 4%, with a current price of 5.82 HKD and a trading volume of 24.98 million HKD [1] - Additionally, non-executive director 胡正国 purchased 1 million shares of 基石药业 at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, increasing his holdings to 3.471 million shares, representing 0.24% of the company [1]